Medical oncology and stem cell services provider TalkMed Group saw its earnings jump 18.5% to $14.3 million for the 2HFY2021 ended December, from $12.1 million a year ago.
This brings earnings for the FY2021 to $25.1 million, 10.3% higher y-o-y.
Earnings per share (EPS) climbed to 1.08 cents in the 2HFY2021 from 0.91 cents a year ago on a fully diluted basis.
In 2HFY2021, revenue for the group inched up by 1.4% y-o-y to $31.9 million mainly due to higher revenue from its 60%-owned subsidiary CellVec, which surged 70.1% y-o-y.
The group’s increase in revenue was also attributable to the higher revenue from its oncology services segment.
These were partly offset by the decrease in revenue derived from the stem cell processing and storage services during the half-year period.
As at end-December, cash and cash equivalents stood at $82.2 million.
The group has proposed a final dividend of 0.90 cents, which is 20% higher than the final dividend of 0.75 cents paid out in the year before.
The final dividend will be paid on May 11.
See also: IHH Healthcare’s 3QFY2024 patmi remains flat at RM534 mil
Shares in TalkMed closed flat at 40 cents on Feb 15.
Photo: Stock image
